ARROWHEAD PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $3.30M.
- ARROWHEAD PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $3.50M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month as first filed | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 113 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 125 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-25 | |||
| 2024-09-30 | $3.30M 10-K · filed 2025-11-25 | -$3.30M 10-K · filed 2024-11-26 | ||
| 2023-09-30 | $0.00 10-K · filed 2024-11-26 | |||
| 2022-09-30 | $3.50M 10-K · filed 2024-11-26 | |||
| 2021-09-30 | $0.00 10-K · filed 2023-11-29 | |||
| 2013-09-30 | $0.00 10-K · filed 2013-12-18 | $0.00 10-K · filed 2013-12-18 | ||
| 2012-09-30 | $0.00 10-K · filed 2013-12-18 | $0.00 10-K · filed 2012-12-28 | ||
| 2011-09-30 | $0.00 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |